Big Pharma, biotech are eyeing PPCH big time
Look all the indicators, fundamentals, PRP and patent, put all combo together, also donot forget they are in that business , where profit is huge way over in chemo drugs.
my target 45cents in few weeks or months and $5-10 dollar in one year
love it here.
if $100 m then -I can not forecast the price.May be teenager this year.
CONSULTING FOR STRATEGIC GROWTH 1 (CFSG) is a leader in reverse mergers, investor and media relations and corporate development. The formation of capital for early-growth stage companies, domestic and international, is one of our core businesses.
In recent years, CFSG has helped raise more than $90 million for domestic and international companies new to the U.S. public marketplace.
With decades of hands-on corporate development experience and broad personal outreach in the private and public investment communities, we place our clients in front of the right decision-makers, market makers and financial gatekeepers – the ones who know your industry, care about your business, and can address your financial needs.
We did before with CELG and VRTX, she is now next, we like the way they are making steady progress, Phase I is not far. Patents are great.PRP will make them rich , the way to treat patients with PRP.
what a chart!
Please do not rush-It will give surprise big time.Can you relax and enjoy the ride.
why you did not buy on friday, I was big line on friday ahead of release.
.0448 will break with no nonsense.
The human pancreas has the largest capacity for protein synthesis of any organ in the human body. Much of the capacity is devoted to synthesis of the digestive enzymes that are secreted in the intestinal lumen. Table 1 lists the major proteolytic, amylolytic, lipolytic and nuclease digestive enzymes [64–66]. Some of the enzymes are present in more than one form (e.g., cationic trypsinogen, anionic trypsinogen and mesotrypsinogen). Further, they are capable of digesting the cell and causing significant damage. There are mechanisms to prevent these enzymes from potentially digesting the pancreas including storage and packing in acidic zymogen granules to inhibit activity; and synthesis and storage as inactive precursor forms. The lists in Table 1 show some of the enzymes that are stored in the pancreas before secretion as inactive proenzymes. These proenzymes are activated when they enter the duodenum. As illustrated in Figure 10, activation of these enzymes takes place in the surface of the duodenal lumen, where a brush-border glycoprotein peptidase, enterokinase, activates trypsinogen by removing (by hydrolysis) an N-terminal hexapeptide fragment of the molecule (Val–Asp–Asp–Asp–Asp–Lys) [65–67]. The active form, trypsin, then catalyzes the activation of the other inactive proenzymes. Of note, many key digestive enzymes, such as α-amylase and lipase, are present in the pancreas in their active forms (Table 1). Presumably, these enzymes would not cause pancreatic cellular damage if released into the pancreatic cell/tissue because there is no starch, glycogen or triglyceride substrate for these enzymes in pancreatic tissue.
TABLE 1. Digestive proenzymes and enzymes in the pancreas. Digestive enzymes are stored in the pancreas as either inactive proenzyme forms or active enzymes.
Phase I filing looks very promising.Do not worry about day to day.Pure target above 5 dollars